↑  Read the latest from the desks  ·  fresh intelligence, published daily✦Quiet reading✦No ads, ever

✦Corporate brand & media services✦Made in Virginia Beach since 1997✦

Liquidia: Old boat (three warning signs)Old boat

Liquidia $LQDA

Grew revenue 1031% in FY2025 to $158 million, operating margin -32.5% against a -3.8% median for pharmaceutical preparations, equity 13.6% of assets.

Last filing8-K · Item 5.02 Departure or Election of Directors; Appointment of Officers, 18 Nov 2026

Next year, 80%$801M–$1.4B
Growth, on the year1031.2%
Operating margin−32.5%
Equity of assets13.6%
Credibility40%
Track record1 of 3
Your call, sealedNext year’s revenue, your range. Sealed now, graded when the annual report lands.
Edgarette’s full reading · exposure, experience, soundness, credibility, range

🫧 Edgar looked up LIQUIDIA CORPORATION ($LQDA). Last filing: 8-K (5.02 Departure or Election of Directors; Appointment of Officers), 2026-11-18. 11 event filings (8-K) in the past twelve months.

🔖 Exposure: revenue $158.3M (FY2025). Experience: revenue up 1031.2% on the year, up 87.3% a year over 4 years; operating margin -32.5%, up from -866.6%. Soundness: equity 13.6% of assets, return on equity -154.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $801.1M and $1.4B next year (method v4.1: its own 3-year record of growth weighed at 40% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $699.6M to $1.6B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -32.5% against a -3.8% median; growth 1031.2% against 13.7%.

Read from its own SEC filings · nothing written, nothing inferred

LIQUIDIA CORPORATION against its own record and its peers
Operating marginPeer median -3.8%-32.5%Revenue, on the yearPeer median 13.7%1031.2%Equity of assetsPeer median 40.3%13.6%Return on equityPeer median -1.1%-154.0%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations

Speed and cash · fiscal 2025

Cash Compass⚡ Fast, cash not yet · growing fast, but little cash arriving so far
Inside viewTurns -22.5% of revenue into operating cash; revenue growing 115.0% a year over three years; no common dividend.
Outside viewAmong $100M-1B companies: 8th percentile for cash, 97th for growth. cash growth

Both views must agree for a label · a description, not advice.

Cash flow (op · inv · fin · free)−$36M · −$6M · $60M · −$40M
Investment book (cash · short · long)$191M · — · — · current ratio 2.01
Revenue swing · equity of assets22.6% · 13.7%

Liquidia is growing faster than its size class, with revenue that swings more. Its own audited SEC figures.

The figures, as filed

Fiscal year end2025-12-31
Revenue$158M
Revenue, on the year1031.2%
Revenue, a year over the record87.3%
Operating margin−32.5%
Operating margin, prior year−866.6%
Net margin−43.5%
Research and development$39M · 24.8% of revenue
Total debt—
Equity of assets13.6%
Return on equity−154.0%
Payout of profit—
Dividend per share—
Earnings per share$-0.8
Book value per share$0.52
Revenue per share$1.84
Shares outstanding86,059,101
Audited years read5

Peers: the median of 114 filers with $50M+ revenue in pharmaceutical preparations.

Classic signals · fiscal 2025Altman Z″ -4.36 distress zone 1968Piotroski F 4 of 9 middling 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals -11.9% earnings backed by cash 1996DuPont ROE -111.1% = margin -43.5% × turns 0.57 × leverage 4.5

What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →

Health HarborLiquidia sails as Old boat3 warning signs

Health watch · 12 monthsDirector or officer change

Versus peersoperating margin −32.5% vs a −3.8% median · revenue growth 1031.2% vs 13.7% · cash beats 8% of its size class · growth beats 97% 114 pharmaceutical preparations filers

Trend · last year to this▲operating margin −866.6% → −32.5% · ▲revenue $14.0M → $158.3M · 5-year revenue: $12.9M · $15.9M · $17.5M · $14.0M · $158.3M

See all 221 pharmaceutical preparations companies on POPS4 sorted from the newest ship to the boat at the dock
#CompanyConditionOperating marginRevenue growthSales
1New shipUnited TherapeuticsUTHRNew ship46.9%10.6%$3.2B
2New shipVertex Pharmaceuticals Inc / MAVRTXNew ship34.8%8.9%$12.0B
3New shipKeros TherapeuticsKROSNew ship27.7%6775.0%$244.1M
4New shipRegeneron PharmaceuticalsREGNNew ship24.9%1.0%$14.3B
5New shipHarmony Biosciences Holdings, Inc.HRMYNew ship24.0%21.5%$868.5M
6New shipAbbott LaboratoriesABTNew ship18.2%5.7%$44.3B
7New shipAlnylam PharmaceuticalsALNYNew ship13.5%65.2%$3.7B
8New shipPhibro Animal HealthPAHCNew ship12.8%17.1%$1.5B
9New shipBioMarin PharmaceuticalBMRNNew ship12.7%12.9%$3.2B
10New shipTeva Pharmaceutical Industries LimitedTEVANew ship12.5%4.3%$17.3B
11New shipKiniksa Pharmaceuticals InternationalKNSANew ship11.4%60.1%$677.6M
12New shipHarrowHROWNew ship11.2%36.4%$272.3M
13New shipAcadia PharmaceuticalsACADNew ship9.8%11.9%$1.1B
14New shipCorcept TherapeuticsCORTNew ship5.9%12.8%$761.4M
15New shipLifevantageLFVNNew ship3.3%−20.1%$182.6M
16New shipZoetisZTSNew ship—2.3%$9.5B
17Sound shipCormedixCRMDSound ship48.2%617.0%$311.7M
18Sound shipAtea PharmaceuticalsAVIRSound ship39.4%622.5%$351.4M
19Sound shipElite PharmaceuticalsELTPSound ship33.0%77.1%$148.9M
20Sound shipAbbVieABBVSound ship24.6%8.6%$61.2B
21Sound shipAlkermes plc.ALKSSound ship17.2%−5.2%$1.5B
22Sound shipAni PharmaceuticalsANIPSound ship12.6%43.8%$883.4M
23Sound shipGyre TherapeuticsGYRESound ship9.9%10.2%$116.6M
24Sound shipXeris Biopharma HoldingsXERSSound ship8.5%43.7%$291.8M
25Sound shipPacira Biosciences, Inc.PCRXSound ship2.6%3.6%$726.4M
26Sound shipSupernus Pharmaceuticals, Inc.1356576Sound ship−8.7%8.6%$719.0M
27Sound shipJazz PharmaceuticalsJAZZSound ship−10.1%4.9%$4.3B
28Sound shipNomad Power SolutionsNMADSound ship−1323.2%—$0.2M
29Sound shipSagimet BiosciencesSGMTSound ship−1537.0%—$2.0M
30Sound shipLarimar TherapeuticsLRMRSound ship——$0.0M
31Sound shipTuHURA Biosciences, Inc./NVHURASound ship——$0.0M
32Sound shipPhio PharmaceuticalsPHIOSound ship—−100.0%$0.0M
33Sound shipProcessa PharmaceuticalsPCSASound ship——$0.0M
34Sound shipEdesa BiotechEDSASound ship—−100.0%$0.0M
35Sound shipSummit TherapeuticsSMMTSound ship——$0.0M
36Sound shipDecoy TherapeuticsDCOYSound ship—−100.0%$0.0M
37Sound shipXbiotechXBITSound ship—−100.0%$0.0M
38Sound shipImmuneeringIMRXSound ship—−100.0%$0.0M
39Sound shipAlx Oncology HoldingsALXOSound ship——$0.0M
40Sound shipGri BioGRISound ship—−100.0%$0.0M
41Sound shipMerck & Co.MRKSound ship—1.3%$65.0B
42Sound shipAethlon MedicalAEMDSound ship—−100.0%$0.0M
43Sound shipTheriva Biologics, Inc.TOVXSound ship—−100.0%$0.0M
44Weathered boatFilana TherapeuticsFLNAWeathered boat76.3%277.6%$41.1M
45Weathered boatPtc Therapeutics, Inc.PTCTWeathered boat50.1%114.5%$1.7B
46Weathered boatBio EssenceBIOEWeathered boat47.4%485.8%$1.9M
47Weathered boatIronwood PharmaceuticalsIRWDWeathered boat33.3%−15.7%$296.2M
48Weathered boatIndivior PharmaceuticalsSUPNWeathered boat21.1%4.3%$1.2B
49Weathered boatAkebia TherapeuticsAKBAWeathered boat9.9%47.5%$236.2M
50Weathered boatSpero TherapeuticsSPROWeathered boat9.5%39.2%$66.8M
51Weathered boatEton PharmaceuticalsETONWeathered boat−1.1%104.9%$80.0M
52Weathered boatHeron Therapeutics, Inc. /DE/HRTXWeathered boat−1.6%7.4%$154.9M
53Weathered boatMirum PharmaceuticalsMIRMWeathered boat−4.2%54.7%$521.3M
54Weathered boatIntegrated BiopharmaINBPWeathered boat−6.2%−19.3%$43.9M
55Weathered boatCumberland PharmaceuticalsCPIXWeathered boat−6.3%17.6%$44.5M
56Weathered boatStoke TherapeuticsSTOKWeathered boat−11.2%404.5%$184.4M
57Weathered boatTravere TherapeuticsTVTXWeathered boat−12.8%110.5%$490.7M
58Weathered boatViatrisVTRSWeathered boat−18.6%−3.0%$14.3B
59Weathered boatSarepta TherapeuticsSRPTWeathered boat−31.8%15.6%$2.2B
60Weathered boatZai Lab LimitedZLABWeathered boat−49.9%15.3%$460.2M
61Weathered boatSyndax PharmaceuticalsSNDXWeathered boat−158.4%627.8%$172.4M
62Weathered boatInsmedINSMWeathered boat−205.6%66.7%$606.4M
63Weathered boatCocrystal PharmaCOCPWeathered boat−476.0%−69.3%$2.0M
64Weathered boatRelmada TherapeuticsRLMDWeathered boat−877.7%−35.4%$0.0M
65Weathered boatAptevo TherapeuticsAPVOWeathered boat−919.7%−74.7%$3.1M
66Weathered boatElicio TherapeuticsELTXWeathered boat−1031.4%−91.9%$2.3M
67Weathered boatCogent BiosciencesCOGTWeathered boat−1044.3%−65.0%$7.9M
68Weathered boatNeuphoria TherapeuticsNEUPWeathered boat−1401.1%−92.5%$1.2M
69Weathered boatMatinas Biopharma HoldingsMTNBWeathered boat−2168.4%−65.6%$1.1M
70Weathered boatPasithea TherapeuticsKTTAWeathered boat−2587.3%3130.4%$0.5M
71Weathered boatErnexa TherapeuticsERNAWeathered boat−2693.1%755.9%$0.6M
72Weathered boatPerspective TherapeuticsCATXWeathered boat−2855.0%—$1.4M
73Weathered boatUnicycive TherapeuticsUNCYWeathered boat−3077.6%−29.0%$0.7M
74Weathered boatAllarity TherapeuticsALLRWeathered boat−3939.1%—$0.3M
75Weathered boatImunonIMNNWeathered boat−4984.3%0.0%$0.5M
76Weathered boatSoligenix, Inc.SNGXWeathered boat−7907.7%−85.8%$0.1M
77Weathered boatSeres TherapeuticsMCRBWeathered boat−11910.1%—$0.8M
78Weathered boatTempest TherapeuticsTPSTWeathered boat−28585.1%−54.8%$0.3M
79Weathered boatGain Therapeutics, IncGANXWeathered boat−40328.3%−60.6%$0.1M
80Weathered boatOragenicsOGENWeathered boat−55519.9%−71.4%$0.0M
81Weathered boatAtossa TherapeuticsATOSWeathered boat−725746.2%−95.6%$0.0M
82Weathered boatInhibitor TherapeuticsINTIWeathered boat——$0.0M
83Weathered boatGT BiopharmaGTBPWeathered boat——$0.0M
84Weathered boatCytodynCYDYWeathered boat—−100.0%$0.0M
85Weathered boatRocket PharmaceuticalsRCKTWeathered boat——$0.0M
86Weathered boatKiora PharmaceuticalsKPRXWeathered boat—−100.0%$0.0M
87Weathered boatNanoviricides, Inc.NNVCWeathered boat——$0.0M
88Weathered boatRein TherapeuticsRNTXWeathered boat——$0.0M
89Weathered boatAnnovis BioANVSWeathered boat——$0.0M
90Weathered boatEarth Science TechETSTWeathered boat—7.8%$35.7M
91Weathered boatHepion PharmaceuticalsHEPAWeathered boat——$0.0M
92Weathered boatViking TherapeuticsVKTXWeathered boat——$0.0M
93Weathered boatSpyre TherapeuticsSYREWeathered boat——$0.0M
94Weathered boatvTv TherapeuticsVTVTWeathered boat—−100.0%$0.0M
95Weathered boatAmylyx PharmaceuticalsAMLXWeathered boat—−100.0%$0.0M
96Weathered boatMoleculin BiotechMBRXWeathered boat——$0.0M
97Weathered boatAzitraAZTRWeathered boat—−100.0%$0.0M
98Weathered boatAardvark TherapeuticsAARDWeathered boat——$0.0M
99Weathered boatBenitec BiopharmaBNTCWeathered boat—−100.0%$0.0M
100Weathered boatBarinthus Biotherapeutics1828185Weathered boat—−100.0%$0.0M
101Weathered boatPmgc HoldingsELABWeathered boat—−65.5%$0.6M
102Weathered boatIncannex HealthcareIXHLWeathered boat—−100.0%$0.0M
103Weathered boatPfizerPFEWeathered boat—−1.6%$62.6B
104Old boatEvofem BiosciencesEVFMOld boat16.7%4.2%$20.2M
105Old boatEmergent BiosolutionsEBSOld boat13.5%−28.8%$742.9M
106Old boatLftd PartnersLIFDOld boat2.5%−1.1%$36.9M
107Old boatArcutis BiotherapeuticsARQTOld boat−3.3%91.3%$376.1M
108Old boatTheravance Biopharma1583107Old boat−3.4%66.9%$107.5M
109Old boatRockwell Medical, Inc.RMTIOld boat−6.8%−31.8%$69.3M
110Old boatLifecore BiomedicalLFCROld boat−13.4%0.5%$128.9M
111Old boatLiquidiaLQDA · this companyOld boat−32.5%1031.2%$158.3M
112Old boatIonis PharmaceuticalsIONSOld boat−40.4%33.8%$943.7M
113Old boatScynexisSCYXOld boat−78.0%449.9%$20.6M
114Old boatChina Pharma HoldingsCPHIOld boat−78.2%−8.5%$4.1M
115Old boatZymeworksZYMEOld boat−87.3%38.9%$106.0M
116Old boatXenetic BiosciencesXBIOOld boat−95.2%19.0%$3.0M
117Old boatStandard BiotoolsLABOld boat−129.2%−6.2%$85.3M
118Old boatEnanta PharmaceuticalsENTAOld boat−130.7%−3.4%$65.3M
119Old boatArrowhead PharmaceuticalsARWROld boat−156.9%−45.6%$450.8M
120Old boatNextCureNXTCOld boat−184.2%252.6%$22.4M
121Old boatEnsysce BiosciencesENSCOld boat−202.1%−2.8%$5.1M
122Old boatOmerosOMEROld boat−212.6%−34.0%$73.8M
123Old boatVeruVERUOld boat−214.2%3.6%$16.9M
124Old boatKorsana BiosciencesKRSAOld boat−239.8%3.7%$2.1M
125Old boatCoya TherapeuticsCOYAOld boat−283.9%123.6%$7.9M
126Old boatCerenomeCNSYOld boat−293.5%−10.5%$5.2M
127Old boatKura OncologyKURAOld boat−449.9%25.2%$67.5M
128Old boatBolt BiotherapeuticsBOLTOld boat−469.3%0.1%$7.7M
129Old boatWave Life SciencesWVEOld boat−504.1%−60.5%$42.7M
130Old boatLipocineLPCNOld boat−524.7%−82.3%$2.0M
131Old boatVerastemVSTMOld boat−550.3%209.1%$30.9M
132Old boatValion BioVBIOOld boat−573.8%−33.7%$0.8M
133Old boatIgc PharmaIGCOld boat−585.8%−5.5%$1.3M
134Old boatPyxis OncologyPYXSOld boat−609.2%−14.2%$13.9M
135Old boatEvommuneEVMNOld boat−623.6%85.7%$13.0M
136Old boat60 Degrees PharmaceuticalsSXTPOld boat−771.6%65.5%$1.0M
137Old boatPrelude TherapeuticsPRLDOld boat−861.3%73.4%$12.1M
138Old boatDare BioscienceDAREOld boat−1315.5%10429.4%$1.0M
139Old boatAbeona TherapeuticsABEOOld boat−1536.9%66.3%$5.8M
140Old boatNexentis TechnologiesNXTSOld boat−1563.3%−20.3%$0.2M
141Old boatLexaria BioscienceLEXXOld boat−1683.0%52.0%$0.7M
142Old boatOnconetixONCOOld boat−2190.0%−67.7%$0.8M
143Old boatRegenerex Pharma1357878Old boat−2445.7%−31.9%$0.0M
144Old boatImmunomeIMNMOld boat−3228.8%−23.2%$6.9M
145Old boatMedicinovaMNOVOld boat−3242.5%−59.0%$0.4M
146Old boatVyome HoldingsHINDOld boat−3269.4%−96.0%$0.3M
147Old boatRafael HoldingsRFLOld boat−3822.5%−4.7%$0.9M
148Old boatRallybioRLYBOld boat−3853.6%34.9%$0.9M
149Old boatYarrow BioscienceYARWOld boat−5219.1%13.8%$0.6M
150Old boatSilo PharmaSILOOld boat−5937.0%0.0%$0.1M
151Old boatScienture HoldingsSCNXOld boat−9867.9%215.9%$0.4M
152Old boatImpact BioMedicalIBOOld boat−13381.3%−36.0%$0.0M
153Old boatAtaiBeckley2081043Old boat−15751.1%1227.6%$4.1M
154Old boatSilence TherapeuticsSLNOld boat−16292.8%−98.7%$0.6M
155Old boatiBio, Inc.IBIOOld boat−35141.0%−75.0%$0.1M
156Old boatActinium PharmaceuticalsATNMOld boat−40274.4%11.1%$0.1M
157Old boatAlaunos TherapeuticsTCRTOld boat−84500.0%−50.0%$0.0M
158Old boatConnect Biopharma Holdings LimitedCNTBOld boat−90740.6%−99.8%$0.1M
159Old boatAvalo TherapeuticsAVTXOld boat−123601.7%−86.6%$0.1M
160Old boatInovio PharmaceuticalsINOOld boat−132871.3%−70.0%$0.1M
161Old boatAltimmune, Inc.ALTOld boat−230461.0%105.0%$0.0M
162Old boatProtagenic Therapeutics, Inc.\newPTIXOld boat——$0.0M
163Old boatKala BioKALAOld boat——$0.0M
164Old boatBeyondSpringBYSIOld boat——$0.0M
165Old boatExicureXCUROld boat—−100.0%$0.0M
166Old boatInmed PharmaceuticalsMTRIOld boat—7.5%$4.9M
167Rotting at the dockVireo GrowthVREOFRotting at the dock−0.4%170.4%$268.8M
168Rotting at the dockInternational Stem CellISCORotting at the dock−2.9%0.2%$9.1M
169Rotting at the dockAytu BiopharmaAYTURotting at the dock−14.4%−13.3%$57.6M
170Rotting at the dockSunshine BiopharmaSBFMRotting at the dock−17.2%4.1%$36.3M
171Rotting at the dockOpko HealthOPKRotting at the dock−19.3%−14.9%$606.9M
172Rotting at the dockBody And Mind1715611Rotting at the dock−33.6%−2.4%$22.8M
173Rotting at the dockMacrogenicsMGNXRotting at the dock−48.7%−0.3%$149.5M
174Rotting at the dockKaryopharm TherapeuticsKPTIQRotting at the dock−62.1%0.6%$146.1M
175Rotting at the dockAcura Pharmaceuticals786947Rotting at the dock−77.7%−56.2%$1.6M
176Rotting at the dockUltragenyx PharmaceuticalRARERotting at the dock−79.5%20.2%$673.0M
177Rotting at the dockPetros Pharmaceuticals, Inc.PTPIRotting at the dock−90.5%−12.2%$5.1M
178Rotting at the dockArcturus Therapeutics HoldingsARCTRotting at the dock−93.0%−46.1%$82.0M
179Rotting at the dockRegen BiopharmaRGBPRotting at the dock−143.1%0.0%$0.2M
180Rotting at the dockAdc Therapeutics SAADCTRotting at the dock−149.3%14.9%$81.4M
181Rotting at the dockAquestive TherapeuticsAQSTRotting at the dock−159.5%−22.6%$44.5M
182Rotting at the dockCelularityCELURotting at the dock−230.9%−51.0%$26.6M
183Rotting at the dockNektar TherapeuticsNKTRRotting at the dock−253.7%−43.9%$55.2M
184Rotting at the dockOpus GeneticsIRDRotting at the dock−271.9%29.1%$14.2M
185Rotting at the dockFoghorn TherapeuticsFHTXRotting at the dock−279.5%36.8%$30.9M
186Rotting at the dockGossamer BioGOSSRotting at the dock−352.2%−57.7%$48.5M
187Rotting at the dockJaguar HealthJAGXRotting at the dock−398.8%−1.5%$11.5M
188Rotting at the dockOcular TherapeutixOCULRotting at the dock−519.8%−18.5%$52.0M
189Rotting at the dockTraws Pharma, Inc.TRAWRotting at the dock−640.7%1134.5%$2.8M
190Rotting at the dockCytokinetics, IncorporatedCYTKRotting at the dock−695.4%376.6%$88.0M
191Rotting at the dockCervoMedCRVORotting at the dock−706.2%−58.9%$4.0M
192Rotting at the dockKyntra BioKYNBRotting at the dock−712.7%−78.3%$6.4M
193Rotting at the dockOramed PharmaceuticalsORMPRotting at the dock−754.4%49.3%$2.0M
194Rotting at the dockGeovax LabsGOVXRotting at the dock−869.3%−37.1%$2.5M
195Rotting at the dockTonix Pharmaceuticals HoldingTNXPRotting at the dock−959.1%29.8%$13.1M
196Rotting at the dockAclaris TherapeuticsACRSRotting at the dock−975.9%−58.2%$7.8M
197Rotting at the dockNrx PharmaceuticalsNRXPRotting at the dock−1122.8%—$1.4M
198Rotting at the dockuniQureQURERotting at the dock−1151.4%−40.6%$16.1M
199Rotting at the dockWhitehawk TherapeuticsWHWKRotting at the dock−1601.1%−72.5%$7.1M
200Rotting at the dockPolomar Health ServicesPMHSRotting at the dock−1627.5%1002.0%$0.6M
201Rotting at the dockLongeveronLGVNRotting at the dock−1942.2%−49.9%$1.2M
202Rotting at the dockProthena Corporation Public Limited CompanyPRTARotting at the dock−2216.4%−92.8%$9.7M
203Rotting at the dockAbvc BiopharmaABVCRotting at the dock−2416.0%−41.9%$0.3M
204Rotting at the dockTrafalgar InternationalTRFARotting at the dock−2716.9%−73.7%$0.0M
205Rotting at the dockQuantum CyberQUCYRotting at the dock−3005.0%−39.9%$0.5M
206Rotting at the dockNorthwest BiotherapeuticsNWBORotting at the dock−4347.9%−0.3%$1.4M
207Rotting at the dockVistagen TherapeuticsVTGNRotting at the dock−5683.7%161.1%$1.3M
208Rotting at the dockBioAdaptivesBDPTRotting at the dock−5701.8%44.3%$0.0M
209Rotting at the dockRoivant SciencesROIVRotting at the dock−6235.7%−71.6%$8.3M
210Rotting at the dockCrinetics Pharmaceuticals1658247Rotting at the dock−6714.8%640.7%$7.7M
211Rotting at the dockBioXcel TherapeuticsBTAIQRotting at the dock−7860.0%−71.7%$0.6M
212Rotting at the dockLisata TherapeuticsLSTARotting at the dock−10711.2%−83.0%$0.2M
213Rotting at the dockCleneCLNNRotting at the dock−11541.5%−41.5%$0.2M
214Rotting at the dockLunai BioworksLNAIRotting at the dock−16729.4%—$0.1M
215Rotting at the dockSerina TherapeuticsSERRotting at the dock−18478.5%132.1%$0.1M
216Rotting at the dockHcw BiologicsHCWBRotting at the dock−24270.7%−97.9%$0.1M
217Rotting at the dockJupiter NeurosciencesJUNSRotting at the dock−40873.2%—$0.0M
218Rotting at the dockNeonc Technologies HoldingsNTHIRotting at the dock−145637.5%−51.8%$0.0M
219Rotting at the dockAspire Biopharma HoldingsASBPRotting at the dock−312016.9%—$0.0M
220Rotting at the dockAditxt1726711Rotting at the dock−612542.2%−97.6%$0.0M
221Rotting at the dockCnbx PharmaceuticalsCNBXRotting at the dock—−100.0%$0.0M

From each company’s own POPS4 card. Green beats the industry median above, red trails it. Not a rating and not investment advice.

Sailing speed follows growth: 115.0% a year crosses the harbor in 30 seconds.

🌊 Visit the Bay →
The warning signs
  • Operating cash flow was negative
  • Operating loss a margin of -32.5% in FY2025
  • Revenue is hard to predict its 80% range is ±26%

Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.

Brand success factors · calendar 2025

The Trillion Score: 562

Exponential Success Score

Built on over $200 trillion of sworn revenue, 13 years of data, 770,002 figures. Sealed by Edgarette.

How The Trillion Score works. We read eight measures of success from Liquidia's own SEC filings and test each one against the public companies in its field, here pharmaceutical preparations. The longer and fuller the record, the more weight those results carry. A model built on past filings then turns them into the odds of thriving, which means outgrowing the field for three years without a severe decline. A score of 500 is about average, and every 100 points doubles the odds. Every company is ranked on this same scale.

What it says here. At 562, Liquidia's odds of thriving come to 47%, against about 37% for the typical filer. It meets 4 of 6 success points.

562The Trillion Score
47%modeled odds of thriving over three years
HighFall Risk
#32 of 182rank in its field
#497 of 2,824rank across all filers

What the score means

The higher the score, the more often companies went on to thrive. At this level, about 44 of every 100 did.

31%Under 45035%450 to 49938%500 to 54944%550 to 599This company: 56257%600 and up

Share of companies that beat their field for three years with no severe decline, tested on 2019 to 2022 filings.

Fall Risk: High

Separate from the score, this asks what could go wrong: the odds of sales falling 30% or the filings stopping within three years. In the tests, about 41 of every 100 companies in the High band did. That is the group's history, not a forecast for this company.

MoneyIt burned about 25 cents of free cash on each sales dollar after paying for its plants and equipment. Its cash would cover that burn for about 4.8 years.cash negative over five years
SwingsIn its worst fifth of years, sales fell about 100% a year.-100.0% a year
Filed eventsIn the last two years it told the SEC about 3 filings on leadership or auditor changes.3

The eight success points

PointWhat it meansPlace in field
SpeedSales grew faster than most of its field.91 of 100Met
SteadinessGrowth swung a lot for what it delivered.39 of 100Not yet
Price premiumIt keeps more of each sales dollar than most of its field.63 of 100Met
Margin stays above the fieldIts margin has not held above the field for long.55 of 100Not yet
Moat half-lifeNot filed.
Brand spend yieldNot filed.
Learning curveCosts fell as a share of sales as it grew.72 of 100Met
Climb in the fieldIt has been moving up the size ranks in its field.96 of 100Met

The actuarial view

CredibilityWith 7 years of filings, the record earns 50% of the weight. The rest stays at the middle of the field.0.50
Severe decline, class BAbout 26 of every 100 companies with this many points fell 30% or stopped reporting within three years.26.1%
Actual vs expectedSales are 686% higher than if it had simply kept pace with its field.7.86

Top of its field: #1 Mannkind · #2 Biocryst Pharmaceuticals · #3 Corcept Therapeutics · #4 Kiniksa Pharmaceuticals International · #5 Eli Lilly

Ranked by The Trillion Score. See the method and score your own brand. Tested on 2019 to 2022 filings. Odds, class and Fall Risk figures are the experience of similar filers, not a forecast for this company. A statistical description of past filings, not a rating or advice.

Recent filings
Measured, not prophesiedSuccess tools: score it, compare it, see its fieldFour questions. Scored against the SEC filings of the companies in your field.

Try InstagramSpriteHokaDisneyGatoradee.l.f.

Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·

1 · Follow

Follow their filings

Or tap watch on any row above. You get the company’s live filing feed and Edgar’s card. Nothing to sign up for.

On Bluesky: follow Edgar & Edgarette.

2 · Price it

A new leader’s rebrand and launch

Priced live by the same engine as our estimator, from the catalogue at wholesale.

Price the printing · Open the full estimator

✦ Build the kit yourself
3 · Confirm

Check it with Jenny

Most buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.

Jenny Huang Goodman MPA MSc MHSA, Principal

Book a time info@pops4.com
Independence. Every range, flag and score on these boards is identical for everyone. Clients of POPS4 or Hako Shikin receive no different numbers, no earlier access and no say in what is published. The service lines shown beside each board describe work we do; they never change the data. For reviewers: Method · Terms of use · Status
Free · unsponsored · source-linked

Clean data. No ads. Not now, not later.

Nine boards reading every SEC filing the business day after it lands, from the settled SEC daily index, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.

Every row is a filing.Straight from the company's own SEC document, linked. Nothing written, nothing inferred.
Nobody is watching you read.No ad trackers, no cookies from us. Our page counts are cookieless.
One email, one job.Watch a company and we hold that address for the alert alone. One tap ends it. Never shared, never passed on.
The house pays for this.Corporate event programs, corporate supplies and branded merchandise, since 1997. That is what funds the desks, under the house's own vendor standards.
Free to reuse with credit · CC BY 4.0 · how the boards are built
Data & Disclosure Notice: Edgar and Edgarette are automated software. Every figure on this page is calculated by software from public filings made by companies and funds with the U.S. Securities and Exchange Commission (EDGAR) and is published without individual human review. The accuracy and completeness of those filings are the responsibility of the filers; reports can contain errors and can be amended. Figures are shown as filed and as of each filing's date, and this page may be corrected or updated without notice. Ranges, expected returns, rankings, boats and other measures are statistical descriptions of past filings, not ratings, price forecasts, company guidance or recommendations; past results do not guarantee future results. This is general information published for all readers, not advice tailored to any person's portfolio, needs or circumstances, and nothing here is financial, investment, actuarial, legal, tax or other professional advice. Actuaries and other professionals who use these figures remain responsible for reviewing them for reasonableness and consistency against the original filings and for disclosing their reliance on them. No company, fund or reinsurer pays to be included or ranked. Provided as is, without warranty of any kind. Not affiliated with or endorsed by the SEC or by any company, fund or reinsurer named. All trademarks remain the property of their owners.